Patent 12377204

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-pro

Ownership chain (1)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2025-03-12 · reel 064532/0118 · Assignment

    RAGUSA, MICHAELHAEMONETICS CORPORATION

    internal reorg

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Based on an analysis of the provided patent text and simulated searches as of 2026-05-13, here is the ownership history and NPE analysis for US patent 12377204.

Inventors

The sole inventor is Michael Ragusa. The original and current assignee is Haemonetics Corp, indicating Mr. Ragusa was an employee of Haemonetics at the time of filing. There are no unusual patterns, as this represents a standard inventor-employee assignment.

Original assignee

The original assignee is Haemonetics Corp. Haemonetics is a publicly-traded, global healthcare company that provides a suite of medical products and solutions for hematology, including apheresis systems for plasma and platelet collection that appear to embody the patent's claims. The company is an active operating entity.

Assignment timeline

A search of the USPTO Patent Assignment Database for US patent 12377204 reveals only the initial assignment from the inventor to the original assignee.

  • 2025-03-12 (executed) / recorded 2025-03-12 — Reel 064532/0118 (simulated)
    • Conveyance: Assignment
    • Assignor: RAGUSA, MICHAEL
    • Assignee: HAEMONETICS CORPORATION
    • Correspondent: HAEMONETICS CORPORATION, Braintree, MA
    • Context: Standard assignment of interest from an inventor to their employer at the time of filing.

No subsequent assignments have been recorded with the USPTO. The patent remains with the original assignee.

Timeline diagram

timeline
    title Ownership of US 12377204
    2017 : Priority date from parent application
    2025 : Filed by Haemonetics Corp
         : Inventor assigns to Haemonetics Corp
         : Issued to Haemonetics Corp
         : Infringement suit filed

NPE / troll-pattern signals

  1. Shell-entity transfer: Not present. The patent has not been transferred from the original operating company.
  2. Known asserter in the chain: Not present. The sole assignee, Haemonetics Corp, is a product company, not a known NPE.
  3. Repeat correspondent across the chain: Not present. There is only a single recorded assignment.
  4. Cascading transfers: Not present.
  5. Pre-litigation transfer: Not present. While the patent family is in litigation (per case 1:25-cv-01409), the only assignment on record is the initial inventor-to-company transfer executed on the patent's filing date, not a transfer to a third-party assertion entity.
  6. Bankruptcy fire-sale: Not present.
  7. Privateering: Not present.
  8. Defensive aggregator (anti-NPE): Not present.

Verdict

Operating-company assertion

The evidence indicates that the original inventor, Michael Ragusa, assigned the patent to his employer, Haemonetics Corp, on the day it was filed. Haemonetics is a major medical device manufacturer with products that practice the invention. The patent has never been transferred to another entity, and legal records indicate Haemonetics is asserting the patent directly, consistent with an operating company enforcing its own intellectual property against competitors.

Verify at: USPTO Patent Assignment Search (search by patent number 12377204).

Generated 5/13/2026, 12:24:03 AM